Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Shan 5 Phase IV Safety and Lot Consistency in Indian Infants
NCT00877357Phase 4Unknown
- Sponsor
- Shantha Biotechnics
- Start
- Jan 2009
- Primary completion
- Dec 2012
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of Shan5 in diphtheria, Tetanus, pertussis and 2 more (3 arms), sponsored by Shantha Biotechnics. Primary endpoint: Solicited and unsolicited local and systemic adverse events at 4 months. Status: unknown.
02
Drugs
Shan5
03
Conditions
diphtheriaTetanuspertussishepatitis B (HBV)Haemophilus influenzae type b infection (Hib)
Beyond the preview
Go deeper on NCT00877357.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00877357.